20-F: Evaxion Reports Strong 2025, MSD Deal Fuels AI Vaccine Pipeline

Evaxion A/S significantly reduced net losses and boosted cash reserves in 2025, driven by a landmark licensing agreement with MSD for its AI-designed vaccine candidate EVX-B3 and promising clinical data for EVX-01.

Summary

• Evaxion A/S reported a net loss of $7.7 million for the year ended December 31, 2025, a significant improvement from a $10.6 million net loss in 2024.
• Revenue increased substantially to $7.5 million in 2025, up from $3.3 million in 2024, primarily due to the licensing of vaccine candidate EVX-B3 to MSD.
• Cash and cash equivalents surged to $23.2 million as of December 31, 2025, compared to $6.0 million at the end of 2024, bolstering liquidity.
• Total equity turned positive, reaching $17.0 million in 2025, a notable recovery from a deficit of $(1.7) million in 2024.
• The company's AI-Immunology platform is central to its strategy, enabling the discovery of novel vaccine targets for cancer and infectious diseases, with plans to expand into autoimmune diseases.
• EVX-01, a personalized cancer vaccine for advanced melanoma, showed highly encouraging two-year Phase 2 clinical efficacy data, including a 75% Objective Response Rate and 25% Complete Response Rate, with 92% of patients still responding at 24 months.
• MSD exercised its option to license EVX-B3, an AI-designed vaccine candidate for a bacterial pathogen, for a $7.5 million cash payment and potential future milestones up to $592 million plus royalties.
• Evaxion is developing EVX-03 (personalized DNA cancer vaccine for solid tumors) and EVX-04 (off-the-shelf therapeutic cancer vaccine for Acute Myeloid Leukemia), with a Phase 1 regulatory filing for EVX-04 expected in H2 2026.
• Preclinical data for EVX-B1 (S. aureus prophylactic vaccine) demonstrated protection against surgical site infections and lethal sepsis, while EVX-B2 (gonorrhea vaccine) showed strong efficacy against 50 clinical strains in mouse models.
• The company initiated a collaboration with the Gates Foundation to apply its AI-Immunology platform to combat polio virus.
• Several changes occurred in executive management, including the appointment of Helen Tayton-Martin as CEO and Thomas Frederik Schmidt as CFO in late 2024/2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive report, reflecting significant progress in financial health, strategic partnerships, and clinical development. The MSD licensing deal and strong EVX-01 data are major milestones, substantially de-risking the company's pipeline and validating its AI platform, despite ongoing losses and the need for future financing.

Positives

• Net loss significantly reduced to $7.7 million in 2025 from $10.6 million in 2024, indicating improved financial performance.
• Revenue more than doubled to $7.5 million in 2025 from $3.3 million in 2024, primarily driven by the MSD licensing deal.
• Cash and cash equivalents increased substantially to $23.2 million by year-end 2025, up from $6.0 million in 2024, enhancing liquidity.
• Total equity turned positive to $17.0 million in 2025 from a deficit of $(1.7) million in 2024, strengthening the balance sheet.
• Successful licensing of EVX-B3 to MSD for an upfront payment of $7.5 million, with potential for up to $592 million in development, regulatory, and sales milestones, plus royalties, validating the AI-Immunology platform.
• Strong two-year Phase 2 clinical efficacy data for EVX-01 in advanced melanoma, showing a 75% Objective Response Rate, 25% Complete Response Rate, and 92% durable response at 24 months with no relapses.
• EVX-01 demonstrated immune activation in all patients, with 81% of vaccine targets triggering a specific response, significantly higher than reported for similar candidates.
• Expansion of the pipeline with new candidates like EVX-B4 (Group A Streptococcus vaccine) and EVX-V1 (Cytomegalovirus vaccine) leveraging the AI-Immunology platform.
• Collaboration with Afrigen Biologics for an mRNA-based gonorrhea vaccine for lowand middle-income countries, and with the Gates Foundation for polio vaccine design, indicating broader impact and external validation.
• Management is confident in having sufficient funds to finance operations into the second half of 2027, with potential for extension through new partnerships.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $126.2 million as of December 31, 2025.
• Reliance on substantial additional financing to achieve goals, with no guarantee of availability on acceptable terms, which could force delays or termination of product development.
• Operating results may fluctuate significantly, making future results difficult to predict, and failure to meet expectations could cause ADS price decline.
• The AI approach to product candidate discovery is novel and unproven, with no guarantee of developing commercially valuable products.
• Clinical drug development is lengthy, expensive, and uncertain, with results of earlier trials not always predictive of future success.
• Interim and preliminary clinical data may differ materially from final results, potentially affecting regulatory approval and commercialization.
• Product candidates may cause undesirable side effects, delaying or preventing regulatory approval or limiting commercial profile.
• Significant management changes, including the departure of the previous CEO, COO, and CFO, could introduce operational disruption or strategic shifts.
• The company does not maintain its own manufacturing capacity and relies on third parties, introducing risks of supply disruptions and regulatory non-compliance.
• Market opportunities for certain product candidates may be limited due to rarity of disease or restriction to specific patient populations, requiring significant market share for profitability.

Risks

• All product candidates are in preclinical and clinical development, with no recurring revenue and no guarantee of commercial revenue for an extended period, if at all.
• Limited operating history and no vaccine approved using the company's technology.
• Dependence on successfully concluding partnerships to advance product candidates and monetize assets.
• Requirement for substantial additional financing, with failure to obtain it potentially leading to delays, limitations, or termination of product development.
• Difficulties in managing company development and expansion, which could disrupt operations.
• Product candidates may not be successful in nonclinical studies or clinical trials, receive regulatory approval, or be successfully commercialized.
• Clinical drug development involves lengthy and expensive processes with uncertain outcomes, and earlier results may not predict future trial outcomes.
• Interim and preliminary data from clinical trials may change as more patient data become available and are subject to audit and verification.
• Pharmaceutical product development is inherently uncertain, with no guarantee of marketing approval for any product candidates.
• Intense competition in the biotechnology and pharmaceutical industries from companies with greater resources.
• Adverse effects on business from geopolitical instability, including conflicts in Ukraine and the Middle East.
• Product candidates may not work as intended, cause undesirable side effects, or have other properties delaying regulatory approval or limiting commercial profile.
• Lengthy, time-consuming, and unpredictable regulatory approval processes by the FDA, EMA, and comparable authorities.
• Future partners may not be able to obtain regulatory approval or effectively commercialize products derived from product candidates.
• Reliance on third parties to manufacture preclinical, clinical, and commercial supplies, and for significant aspects of preclinical studies and clinical trials.
• Potential difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management, or shipping.
• Challenges in scaling manufacturing capabilities for personalized therapies.
• Inability to obtain, maintain, protect, defend, or enforce intellectual property rights, leading to competitive disadvantage.
• Involvement in costly and time-consuming intellectual property lawsuits.
• Challenges with the acquisition, development, enhancement, or deployment of technology necessary for the AI-Immunology platform.
• Difficulties in monitoring patient safety in clinical trials, potentially leading to severe toxicities or patient deaths.
• Inability to develop or obtain approval for companion diagnostics required for certain product candidates.
• Regulatory authorities may not consider clinical trial endpoints to provide clinically meaningful results.
• Ongoing regulatory obligations and continued review for approved products, potentially resulting in significant additional costs, restrictions, or penalties.
• Government funding constraints or disruption affecting regulatory authorities could delay product development, review, and approval.
• Future pandemics, epidemics, or outbreaks of infectious disease could materially disrupt operations.
• Global and regional economic, political, health, climate, and other conditions could adversely affect the business.
• Dependence on the availability of key raw materials, which may not be obtainable on acceptable terms or at all.
• Product candidates are sensitive to shipping and storage conditions and may be subject to loss or damage.
• Market opportunities for certain product candidates may be limited due to rarity of disease or restriction to specific patient populations.
• Reliance on future partners for commercialization, who may not successfully commercialize product candidates.
• Uncertainty regarding coverage and adequate reimbursement levels from governmental authorities, private health insurers, and other third-party payors.
• Healthcare reform and other legislative changes may increase costs and complexity of commercialization and impose pricing limitations.
• European Union drug pricing and reimbursement regulations may limit commercial potential.
• Existing collaborations and any future collaboration arrangements may not be successful.
• Inability to establish collaborations on commercially reasonable terms may alter research and development plans.
• Failure to comply with license agreements or loss of rights to in-licensed intellectual property.
• Reliance on single-source suppliers for critical components and materials.
• Third-party intellectual property rights could prevent development or commercialization, requiring costly litigation or licenses.
• Failure to comply with patent office requirements could result in loss of patent rights.
• Changes in patent laws could reduce the value of intellectual property.
• Inability to protect the confidentiality of trade secrets.
• Claims of misappropriation of third-party confidential information or trade secrets.
• Claims challenging inventorship or ownership of intellectual property.
• Lack of patent protection in all jurisdictions and limited enforceability where protection is weak.
• Inadequate protection of trademarks and trade names.
• Intellectual property rights may not address all potential threats or maintain competitive advantage.
• Reliance on information technology systems, with risks of failure, interruption, or security breach.
• Exposure to extensive federal, state, and foreign healthcare laws and regulations, including fraud and abuse laws.
• Subject to anti-corruption, anti-money laundering, export control, sanctions, and other trade laws.
• Stringent privacy laws, information security policies, and contractual obligations governing personal information.
• Failure to comply with environmental, health, and safety regulations.
• Inability to attract and retain key personnel.
• Product liability claims could result in significant costs.
• Product recalls could harm business and reputation.
• Future acquisitions, joint ventures, partnerships, or collaborations could involve significant risks and costs.
• Global climate change and ESG requirements could adversely affect the business.
• Natural disasters or catastrophic events could disrupt operations.
• Market price volatility of ADSs, influenced by broad market and industry factors.
• Lack of sustained active and liquid market for ADSs and ordinary shares.
• Significant costs and risks related to compliance with public company reporting and governance requirements.
• Reduced disclosure requirements as an emerging growth company may make ADSs less attractive to investors.
• Exemptions as a foreign private issuer may limit information and protections for ADS holders.
• Failure to meet Nasdaq's continued listing requirements could result in delisting.
• Loss of foreign private issuer status would increase regulatory burden and cost.
• Limitations on transfer of ADSs and withdrawal of underlying ordinary shares.
• Potential significant sale of outstanding ordinary shares in the near future, causing dilution and depressing ADS price.
• FINRA sales practice requirements may limit stockholders' ability to buy and sell securities.
• Limited voting rights for ADS holders compared to shareholders.
• Future issuance of ordinary shares or ADSs could cause dilution.
• Shareholder rights under Danish law differ from U.S. law and may provide less protection.
• Holders of ordinary shares or ADSs may not be able to exercise pre-emptive rights and could be diluted.
• United States holders of ADSs may face adverse tax consequences if classified as a passive foreign investment company (PFIC).
• Uncertainty regarding Danish tax treatment of ADSs.
• Claims of United States civil liabilities may not be enforceable against the company.
• Failure to meet guidance or market expectations could adversely affect ADS price.
• Securities or industry analysts not publishing research or negative evaluations could decline ADS price and trading volume.
• Principal shareholders and executive management hold significant ownership and may exert substantial influence over shareholder decisions.
• Broad discretion in the use of funds, which may not be applied effectively.
• Insufficient funds to satisfy obligations to the European Investment Bank upon warrant exercise.

Future Outlook

Evaxion expects to remain in the development stage for the upcoming year, focusing on advancing its AI platforms and related models, supporting future partners in seeking regulatory approvals, and scaling up manufacturing. The company aims to extend its cash runway through business development deals or partnership agreements in 2026. They plan to submit a regulatory filing for a Phase 1 trial for EVX-04 in H2 2026 and expect three-year Phase 2 clinical efficacy data for EVX-01 in H2 2026, along with additional biomarker and immunogenicity data in H1 2026. The company also plans to expand its AI-Immunology platform into autoimmune diseases in H2 2026 and conclude design and preclinical validation of antigens for EVX-B4 in H2 2026.

Management Comments

• Management and the Board of Directors are confident that the Company will continue its operations for at least the next 12 months, and with current strategic plans and forecasted cash burn, sufficient cash is available to finance operations into the second half of 2027.
• If we are successful in delivering business development deals or partnership agreements during 2026, we will further extend our cash runway.

Industry Context

StockSavvy.ai notes that Evaxion operates in the rapidly growing AI-based drug discovery market, projected to reach over $40 billion by 2040, driven by demand for advanced therapeutics and rising chronic disease prevalence. The company's focus on novel vaccines for cancer and infectious diseases addresses massive unmet medical needs, with the global cancer immunotherapy market projected to grow to $229 billion by 2030 and infectious disease vaccines to $68 billion by 2031. Evaxion's strategy of leveraging its AI-Immunology platform for target discovery and early-stage development, followed by partnerships with larger biopharmaceutical companies like MSD, aligns with industry trends where specialized biotech firms innovate and larger players provide late-stage development and commercialization resources. The successful licensing of EVX-B3 to MSD is a significant validation of AI-driven vaccine discovery in a highly competitive landscape.

Comparison to Industry Standards

• EVX-01's 81% vaccine neoantigen targets triggering a tumor-specific immune response is substantially higher than what has been reported for other similar vaccine candidates in the industry, indicating superior immunogenicity.
• The 75% Objective Response Rate and 25% Complete Response Rate for EVX-01 in advanced melanoma, with 92% durable response at 24 months, are highly encouraging compared to typical response rates for existing therapies in this challenging indication.
• The licensing deal with MSD for EVX-B3, with potential milestones up to $592 million, positions Evaxion favorably against other early-stage biotech companies by securing significant non-dilutive funding and external validation from a world leader in vaccine development.
• Evaxion's AI-Immunology platform is described as faster, cheaper, and more accurate than conventional methods like reverse vaccinology, suggesting a competitive advantage in drug discovery efficiency.
• The development of vaccines for diseases like gonorrhea and Group A Streptococcus, for which no vaccines currently exist despite decades of research, highlights Evaxion's potential to address significant unmet medical needs where traditional approaches have failed.

Management Changes

Corporate Governance

Legal Proceedings

• There are no governmental, legal, or arbitration proceedings (pending or threatened) that have had significant effects on Evaxion's financial position or profitability in the past 12 months.
• A legal proceeding initiated by Statens Serum Institut (SSI) in April 2022 claiming sole ownership of a patent application was settled on June 27, 2024, with Evaxion and SSI agreeing to co-ownership and Evaxion retaining all commercial rights.

Related Party Transactions

• No grants, agreements, or transactions exceeding $120,000 involving directors, executive management, or 10%+ shareholders, or their immediate families, with a direct or indirect material interest, other than remuneration and capital increases on the same terms as other investors.
• Share-based awards have been granted to certain directors and executive management as part of the warrant incentive program.
• Employment agreements have been entered into with each member of the executive management.
• Indemnification agreements are intended to be entered into with each director and member of executive management and employees.

Stakeholder Impact

• **Shareholders:** Positive impact from reduced net losses, increased revenue, improved liquidity, and positive clinical data for EVX-01. Potential for future value creation from the MSD licensing deal and pipeline advancements. Dilution risk from ongoing equity financings and warrant exercises. Enhanced governance through new policies.
• **Employees:** Continued employment and warrant incentive programs. Significant management changes may lead to shifts in company culture or priorities. Cybersecurity risks could impact employee data.
• **Customers (future patients):** Potential for novel vaccines for cancer and infectious diseases addressing high unmet medical needs. EVX-01's strong clinical data offers hope for advanced melanoma patients. EVX-B3's licensing to MSD could accelerate its development and availability.
• **Suppliers/Partners:** Continued reliance on third-party manufacturers and CROs, providing business opportunities but also exposing the company to supply chain risks. Successful collaborations like MSD and Gates Foundation validate the company's platform and attract further partnerships.
• **Creditors:** Improved liquidity and equity position reduce immediate credit risk. Conversion of EIB loan to equity also reduces debt obligations.

Next Steps

• Present additional biomarker and immunogenicity data for EVX-01 at a scientific conference in H1 2026.
• Read out three-year Phase 2 clinical efficacy data for EVX-01 (monotherapy extension) in H2 2026.
• Submit regulatory filing for a Phase 1 trial for EVX-04 (AML vaccine) in H2 2026.
• Expand AI-Immunology platform application to autoimmune diseases in H2 2026.
• Conclude design and preclinical validation of antigens for EVX-B4 (Group A Streptococcus vaccine) in H2 2026.
• Continue to identify potential collaborators to expand impact to broader patient populations.
• Monitor funding situation closely and prepare for new financing transactions and/or adjust cost base as needed.
• Potentially utilize the financing agreement with Global Growth Holding Limited (GGH) for convertible notes, pending SEC approval.

Key Dates

Recommendation

Evaxion's 2025 results show significant financial improvement, driven by a substantial increase in revenue from the MSD licensing deal and a notable reduction in net losses. The strong two-year Phase 2 data for EVX-01 in advanced melanoma is highly encouraging and validates the AI-Immunology platform. The company's liquidity position has also improved considerably. However, Evaxion remains a clinical-stage company with an accumulated deficit, requiring substantial future financing. While the MSD deal provides a significant non-dilutive funding source and external validation, the path to profitability is still long and subject to numerous clinical, regulatory, and commercialization risks inherent in biotech. The recent management changes, while potentially positive long-term, introduce a period of transition. Given the strong positive developments balanced against the inherent risks and the need for continued capital, a 'hold' recommendation is appropriate for seasoned investors, allowing for observation of further pipeline progression and financial stability without immediate aggressive action.

Keywords

AI-Immunology, Vaccine Development, Cancer Vaccines, Infectious Disease Vaccines, Biotechnology, Pharmaceutical, Clinical Trials, Preclinical Development, EVX-01, EVX-B3, MSD Partnership, Melanoma, Acute Myeloid Leukemia, S. aureus, Gonorrhea, Cytomegalovirus, SEC Filing, Financial Results, Liquidity, Capital Raise, Corporate Governance, Intellectual Property, Nasdaq